Imsidolimab, a novel IgG4 IL36 receptor antagonist, was effective and well tolerated in patients with GPP
Sandra Smieszek
Pro |
Presented at: Society for Investigative Dermatology 2025
Date: 2025-05-07 00:00:00
Views: 42
Summary: Content is hidden. So this is just placeholder text should someone try to view the source of the content. You thought you could get away with it, didn't you? Now look at you just continuing to scroll. Have a great day!